SYBLEU (SYBE) 10-K 22 Jul 22 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2022	Jul. 16, 2022	Dec. 31, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	333-248059
Entity Registrant Name	SYBLEU INC
Entity Central Index Key	0001818674
Entity Tax Identification Number	85-1412307
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	Suite 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	(619)
Local Phone Number	227-9192
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		10,418,000
Auditor Name	BF Borgers CPA PC
Auditor Firm ID	5041
Auditor Location	Lakewood, CO

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Jun. 30, 2022	Jun. 30, 2021
CURRENT ASSETS
Cash	$ 66,850	$ 14,297
Prepaid Expenses	0	0
Total Current Assets	66,850	14,297
OTHER ASSETS
Investment Securities	9,529	185,250
Total Other Assets	9,529	185,250
TOTAL ASSETS	76,379	199,547
Current Liabilities:
Income Taxes Payable	10,935	21,394
Notes Payable	140,000	0
Notes Payable, Related Party	0	8,919
Expenses Accrued but Unpaid	452	450
Interest Accrued but Unpaid	13,253	0
Total Current Liabilities	164,640	30,763
Long Term Liabilities:
Unearned Income	161,699	173,398
Total Liabilities	326,338	204,161
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001 10,418,000 shares issued and outstanding as of June 30, 2022 and June 30,2021	1,042	1,042
Additional Paid in capital	100,049	100,049
Retained Earnings (Deficit )	(351,051)	(105,705)
Total Stockholders' Equity (Deficit)	(249,960)	(4,614)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 76,379	$ 199,547

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	10,418,000	10,418,000
Common Stock, Shares, Outstanding	10,418,000	10,418,000

STATEMENT OF OPERATIONS

STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
REVENUES
License Fees	$ 11,700	$ 4,052
TOTAL REVENUES	11,700	4,052
Research and Development:
Consulting Costs	0	26,311
Patent Application Costs	5,058	3,100
Total Research and Development	5,058	29,411
General and Administrative:
Transfer Agency Fees	1,884	6,115
Other General and Administrative Expenses	13,731	1,898
Total General and Administrative	15,616	8,013
Consulting:
Legal Fees	0	500
Accounting	47,400	11,880
Other Consulting	0	13,600
Information Technology Consulting	0	23,900
Total Consulting	47,400	49,880
Rent		5,000
Total Costs and Expenses	68,073	92,304
OPERATING Income(LOSS)	(56,374)	(88,252)
OTHER INCOME AND EXPENSES
Unrealized Gain (Loss) on Investment Securities	(175,721)	7,800
Interest Income(Expense)	(13,252)	0
TOTAL OTHER INCOME (EXPENSES)	(188,973)	7,800
NET INCOME (LOSS) Before Taxes	(245,347)	(80,452)
Provision for Income Taxes	0	(21,394)
NET INCOME (LOSS)	$ (245,347)	$ (101,846)
BASIC AND FULLY DILUTED
LOSS PER SHARE	$ (0.02)	$ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING	10,418,000	10,054,932

STATEMENT OF SHAREHOLDERS EQUIT

STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2020	$ 935	$ 145	$ (3,859)	$ (2,779)
Beginning balance, shares at Jun. 30, 2020	9,353,000
Common shares issued for nonemployee services July 8,2020	$ 7	4		11
Common shares issued for nonemployee services, shares	65,000
Net Income Quarter Ended June 30, 2021			(21,896)	(21,896)
Ending balance, value at Sep. 30, 2020	$ 942	149	(25,755)	(24,664)
Ending balance, shares at Sep. 30, 2020	9,418,000
Beginning balance, value at Jun. 30, 2020	$ 935	145	(3,859)	(2,779)
Beginning balance, shares at Jun. 30, 2020	9,353,000
Ending balance, value at Jun. 30, 2021	$ 1,042	100,049	(105,705)	(4,614)
Ending balance, shares at Jun. 30, 2021	10,418,000
Beginning balance, value at Sep. 30, 2020	$ 942	149	(25,755)	(24,664)
Beginning balance, shares at Sep. 30, 2020	9,418,000
Common Stock issued for cash November  9 2020	$ 100	99,900		100,000
Stock Issued During Period, Shares, New Issues	1,000,000
Net Income Quarter Ended June 30, 2021			(34,463)	(34,463)
Ending balance, value at Dec. 31, 2020	$ 1,042	100,049	60,218	40,873
Ending balance, shares at Dec. 31, 2020	10,418,000
Net Income Quarter Ended June 30, 2021			86,599	(86,599)
Ending balance, value at Mar. 31, 2021	$ 1,042	100,049	(146,817)	(45,726)
Ending balance, shares at Mar. 31, 2021	10,418,000
Net Income Quarter Ended June 30, 2021			41,112	41,112
Ending balance, value at Jun. 30, 2021	$ 1,042	100,049	(105,705)	(4,614)
Ending balance, shares at Jun. 30, 2021	10,418,000
Net Income Quarter Ended June 30, 2021			(132,307)	(132,307)
Ending balance, value at Sep. 30, 2021	$ 1,042	100,049	(238,012)	(136,921)
Ending balance, shares at Sep. 30, 2021	10,418,000
Beginning balance, value at Jun. 30, 2021	$ 1,042	100,049	(105,705)	(4,614)
Beginning balance, shares at Jun. 30, 2021	10,418,000
Ending balance, value at Jun. 30, 2022	$ 1,042	100,049	(351,051)	(249,960)
Ending balance, shares at Jun. 30, 2022	10,418,000
Beginning balance, value at Sep. 30, 2021	$ 1,042	100,049	(238,012)	(136,921)
Beginning balance, shares at Sep. 30, 2021	10,418,000
Net Income Quarter Ended June 30, 2021			(61,751)	(61,751)
Ending balance, value at Dec. 31, 2021	$ 1,042	100,049	(299,763)	(198,672)
Ending balance, shares at Dec. 31, 2021	10,418,000
Net Income Quarter Ended June 30, 2021			(27,030)	(27,030)
Ending balance, value at Mar. 31, 2022	$ 1,042	100,049	(326,793)	(225,702)
Ending balance, shares at Mar. 31, 2022	10,418,000
Net Income Quarter Ended June 30, 2021			(24,258)	(24,258)
Ending balance, value at Jun. 30, 2022	$ 1,042	$ 100,049	$ (351,051)	$ (249,960)
Ending balance, shares at Jun. 30, 2022	10,418,000

STATEMENT OF CASH FLOWS

STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (245,347)	$ (101,846)
Adjustments to reconcile net Income (loss) to net cash
Common Stock Issued for payment of expenses		11
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses		3,500
Increase (Decrease) in Accrued Expenses	13,257	450
(Increase) Decrease in Securities accepted as  Payment		(177,450)
Increase(Decrease) in Unearned Income	(11,700)	173,398
Increase (Decrease) in Income Tax Payable	(10,459)	21,394
Unrealized Loss ( Gain) in Investment Securities	175,721	(7,800)
Net Cash provided by (used) in Operating Activities	(78,528)	(88,343)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Notes Payable, Related Parties	(8,919)	(2,410)
Increase (Decrease) in Notes Payable	140,000
Common Stock issued for Cash		100,000
Net Cash provided by (used) in Financing Activities	131,081	97,590
Net Increase (Decrease) in Cash	52,553	9,247
Cash at Beginning of Period	14,297	5,050
Cash at End of Period	66,850	14,297
Supplemental Cash Flow Information:
Interest Paid
Income Taxes Paid	$ 10,459

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming. The Company intends to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end. B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application. F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the year ended June 30, 2022 no Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable During the year ended June 30, 2022 no Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2022 the Company had no The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2022.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements. On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This guidance is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated net losses of $ 351,051 Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4. RELATED PARTY TRANSACTIONS The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by BST Partners, Inc. on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. BST Partners, Inc. is a company controlled by SYBLEU’s Chairman and CEO.

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTES PAYABLE Schedule of related party debt Bostonia Partners 140,000 Notes Payable, as of June 30, 2022 $ 140,000 $ 10,000 10 September 20,2022 $ 30,000 10 September 30,2022 $ 100,000 10 October 5,2022

INVESTMENT SECURITIES

INVESTMENT SECURITIES	12 Months Ended
	Jun. 30, 2022
Schedule of Investments [Abstract]
INVESTMENT SECURITIES	NOTE 6. INVESTMENT SECURITIES On March 11, 2021 the Company was paid 6,500 On June 30 2022 the Company revalued 6,500 As of June 30, 2022: Schedule Of Common Shares 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the Quarter ended June 30,2022 $ 177,450 $ 9,529 $ (167,921 ) $ (14,521 )

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following class of capital stock as of June 30, 2022: Common stock, $ 0.0001 100,000,000 10,418,000 With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 9. INCOME TAXES As of June 30, 2022 Schedule of Deferred Tax Assets Deferred tax assets: Net operating tax carry forwards $ 80,876 Other 0 Gross deferred tax assets 80,876 Valuation allowance (80,876 ) Net deferred tax assets $ 0 As of June 30, 2022 the Company has a Deferred Tax Asset of $ 80,876 60,219 Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, if as a result of a stock transfer or a reorganization, a corporation undergoes an “ownership change,” Code Section 382 limits the corporation’s right to use its NOLs each year thereafter to an annual percentage of the fair market value of the corporation at the time of the ownership change (the “Section 382 Limitation”). A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders. Income tax is calculated at the 21

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	12 Months Ended
	Jun. 30, 2022
Restatement Of Previously Issued Financial Statements
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	NOTE 10. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS Subsequent to the original issuance of the Company’s quarterly financial statements for the year ended June 30, 2021 the Company determined that the following revisions are required Recognizing revenue of $ 177,450 15 years Cumulative Effect of Restatement of Previously Issued Financial Statements for the Year Ended Ended June 30 2021. Schedule of restatement of previously issued Financial Statements Year Ended June 30, 2021 Balance Sheet As Originally Presented Adjustments As Restated Unearned Income 0 173,398 173,398 Total Liabilities: 30,763 173,398 204,161 Retained Earnings (Deficit ) 67,693 (173,398 ) (105,705 ) Total Stockholders' Equity (Deficit) 168,784 (173,398 ) (4,614 ) Year Ended June 30, 2021 Statement of Operations As Originally Presented Adjustments As Restated License Fees 177,450 (173,398 ) 4,052 Total Revenue 177,450 (173,398 ) 4,052 Operating Income ( Loss) 85,146 (173,398 ) (88,252 ) Net Income (Loss )Before Taxes 92,946 (173,398 ) (80,452 ) Net Income (Loss ) 71,552 (173,398 ) (101,846 ) Year Ended June 30, 2021 Statement of Shareholders' Equity ( Deficit) As Originally Presented Adjustments As Restated Net Income ( Loss) Quarter ended March 31, 2021 89,716 — 89,716 Retained Deficit March 31, 2021 29,498 (176,315 ) (146,817 ) Total Stockholders' Equity (Deficit) March 31, 2021 130,589 (176,315 ) (45,726 ) Net Income ( Loss) Quarter ended June 30, 2021 38,195 (173,398 ) (135,203 ) Retained Deficit June 30, 2021 67,693 (173,398 ) (105,705 ) Total Stockholders' Equity (Deficit) June 30, 2021 168,784 (173,398 ) (4,614 ) Year Ended June 30, 2021 Statement of Cash Flows As Originally Presented Adjustments As Restated Net Income (Loss) 38,195 (173,398 ) (135,203 ) Increase ( Decrease) in Unearned Income 0 173,398 173,398

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
FAIR VALUE OF FINANCIAL INSTRUMENTS	D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
RESEARCH AND DEVELOPMENT COSTS	E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.
STOCK BASED COMPENSATION	F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the year ended June 30, 2022 no Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable During the year ended June 30, 2022 no Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete.
INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2022 the Company had no The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2022.

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of related party debt	Schedule of related party debt Bostonia Partners 140,000 Notes Payable, as of June 30, 2022 $ 140,000

INVESTMENT SECURITIES (Tables)

INVESTMENT SECURITIES (Tables)	12 Months Ended
	Jun. 30, 2022
Schedule of Investments [Abstract]
Schedule Of Common Shares	Schedule Of Common Shares 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the Quarter ended June 30,2022 $ 177,450 $ 9,529 $ (167,921 ) $ (14,521 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Schedule of Deferred Tax Assets Deferred tax assets: Net operating tax carry forwards $ 80,876 Other 0 Gross deferred tax assets 80,876 Valuation allowance (80,876 ) Net deferred tax assets $ 0

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Jun. 30, 2022
Restatement Of Previously Issued Financial Statements
Schedule of restatement of previously issued Financial Statements	Schedule of restatement of previously issued Financial Statements Year Ended June 30, 2021 Balance Sheet As Originally Presented Adjustments As Restated Unearned Income 0 173,398 173,398 Total Liabilities: 30,763 173,398 204,161 Retained Earnings (Deficit ) 67,693 (173,398 ) (105,705 ) Total Stockholders' Equity (Deficit) 168,784 (173,398 ) (4,614 ) Year Ended June 30, 2021 Statement of Operations As Originally Presented Adjustments As Restated License Fees 177,450 (173,398 ) 4,052 Total Revenue 177,450 (173,398 ) 4,052 Operating Income ( Loss) 85,146 (173,398 ) (88,252 ) Net Income (Loss )Before Taxes 92,946 (173,398 ) (80,452 ) Net Income (Loss ) 71,552 (173,398 ) (101,846 ) Year Ended June 30, 2021 Statement of Shareholders' Equity ( Deficit) As Originally Presented Adjustments As Restated Net Income ( Loss) Quarter ended March 31, 2021 89,716 — 89,716 Retained Deficit March 31, 2021 29,498 (176,315 ) (146,817 ) Total Stockholders' Equity (Deficit) March 31, 2021 130,589 (176,315 ) (45,726 ) Net Income ( Loss) Quarter ended June 30, 2021 38,195 (173,398 ) (135,203 ) Retained Deficit June 30, 2021 67,693 (173,398 ) (105,705 ) Total Stockholders' Equity (Deficit) June 30, 2021 168,784 (173,398 ) (4,614 ) Year Ended June 30, 2021 Statement of Cash Flows As Originally Presented Adjustments As Restated Net Income (Loss) 38,195 (173,398 ) (135,203 ) Increase ( Decrease) in Unearned Income 0 173,398 173,398

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Jun. 30, 2022 USD ($) shares
Defined Benefit Plan Disclosure [Line Items]
Uncertain tax positions | $	$ 0
Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued for compensation	0
Non Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued for services	0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	25 Months Ended
	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income loss	$ 351,051

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)	Jun. 30, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	$ 140,000
Bostonia Partners [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	$ 140,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)	12 Months Ended
	Jun. 30, 2022 USD ($)
Bostonia Partners [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 10,000
Interest rate	10%
Maturity date	Sep. 20, 2022
Bostonia Partners 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 30,000
Interest rate	10%
Maturity date	Sep. 30, 2022
Bostonia Partners 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 100,000
Interest rate	10%
Maturity date	Oct. 05, 2022

INVESTMENT SECURITIES (Details)

INVESTMENT SECURITIES (Details) - Oncology Pharma Inc [Member]	12 Months Ended
	Jun. 30, 2022 USD ($)
Schedule of Investments [Line Items]
Investment securities, basis	$ 177,450
Investment securities, fair value	9,529
Investment securities, total unrealized losses	(167,921)
Investment securities, net unrealized gain or loss realized	$ (14,521)

INVESTMENT SECURITIES (Details

INVESTMENT SECURITIES (Details Narrative) - shares		12 Months Ended
	Mar. 11, 2021	Jun. 30, 2022
Oncology Pharma Inc [Member]
Schedule of Investments [Line Items]
Number of shares issued for property dividend	6,500	6,500

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,418,000	10,418,000
Common stock, shares outstanding	10,418,000	10,418,000

INCOME TAXES (Details)

INCOME TAXES (Details)	Jun. 30, 2022 USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 80,876
Other	0
Gross deferred tax assets	80,876
Valuation allowance	(80,876)
Net deferred tax assets	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	12 Months Ended
	Jun. 30, 2022 USD ($)
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 80,876
Net operating loss carry forwards	$ 60,219
Federal Corporate Rate	21%

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details) - USD ($)	3 Months Ended								12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2022	Jun. 30, 2021
Total Liabilities	$ 326,338				$ 204,161				$ 326,338	$ 204,161
Retained Deficit	(351,051)				(105,705)				(351,051)	(105,705)
License Fees									11,700	4,052
Operating Income ( Loss)									(56,374)	(88,252)
Net Income (Loss )									(245,347)	(101,846)
Net Income (Loss)	$ (24,258)	$ (27,030)	$ (61,751)	$ (132,307)	41,112	$ (86,599)	$ (34,463)	$ (21,896)
Increase ( Decrease) in Unearned Income									(11,700)	173,398
As Originally Presented [Member]
Unearned Income					0					0
Total Liabilities					30,763					30,763
Retained Deficit					67,693					67,693
Total Stockholders' Equity (Deficit)					168,784	130,589				168,784
License Fees										177,450
Total Revenue										177,450
Operating Income ( Loss)										85,146
Net Income (Loss )Before Taxes										92,946
Net Income (Loss )										71,552
Net Income (Loss)					38,195	89,716				38,195
Retained Deficit					67,693	29,498				67,693
Increase ( Decrease) in Unearned Income										0
Revision of Prior Period, Adjustment [Member]
Unearned Income					173,398					173,398
Total Liabilities					173,398					173,398
Retained Deficit					(173,398)	(176,315)				(173,398)
Total Stockholders' Equity (Deficit)					(173,398)	(176,315)				(173,398)
License Fees										(173,398)
Total Revenue										(173,398)
Operating Income ( Loss)										(173,398)
Net Income (Loss )Before Taxes										(173,398)
Net Income (Loss )										(173,398)
Net Income (Loss)					(173,398)					(173,398)
Retained Deficit					(173,398)					(173,398)
Increase ( Decrease) in Unearned Income										173,398
As Restated [Member]
Unearned Income					173,398					173,398
Total Liabilities					204,161					204,161
Retained Deficit					(105,705)	(146,817)				(105,705)
Total Stockholders' Equity (Deficit)					(4,614)	$ (45,726)				(4,614)
License Fees										4,052
Total Revenue										4,052
Operating Income ( Loss)										(88,252)
Net Income (Loss )Before Taxes										(80,452)
Net Income (Loss )										(101,846)
Net Income (Loss)					(135,203)				$ 89,716	(135,203)
Retained Deficit					$ (105,705)					(105,705)
Increase ( Decrease) in Unearned Income										$ 173,398

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2022
Restatement Of Previously Issued Financial Statements
Licensing fees	$ 177,450
License term		15 years